Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Translational Lung Cancer ResearchOpen Access

Survival outcomes and risk factors after lung transplantation in patients with pre-transplant malignancy: a national cohort study

View Full Paper
Ask AI
Bookmark
Share

Authors

XLXiaoqing LanFirst Affiliated Hospital of Guangzhou Medical UniversityCLCaikang LuoFirst Affiliated Hospital of Guangzhou Medical UniversityJHJunjie HeWenzhou University

Discussion

Loading...

Member takes

Implication

National cohort study finds higher mortality in lung transplant patients with pre-transplant malignancy, suggesting critical risk factors.

Key Points

  • Patients with pre-transplant malignancy exhibit a higher mortality rate after lung transplantation.
  • Survival analysis indicates significant mortality differences based on malignancy type and other risk factors.
  • Kaplan-Meier and Cox models revealed age and lung allocation score as key predictors of long-term mortality.
  • Emphasizing careful selection for long-term lung transplant candidates with certain malignancies is crucial.

Cite This Study

Lan et al. (2025) studied this question.

synapsesocial.com/papers/68c1a25354b1d3bfb60dcc7fhttps://doi.org/10.21037/tlcr-2025-224
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Rethinking the Impact of Pretransplant Malignancy (Pre-TM) on Double Lung Transplantation (DLT) Eligibility: An Analysis of 23,291 DLT Recipients2024
  2. 2Rethinking the impact of pretransplant malignancy on eligibility for double lung transplantation (DLT): An analysis of 23,291 recipients.2024
  3. 3Malignancy risk and mortality after lung transplantation: A single-institution experience over 31 years2024 · 8 citations
  4. 4Outcomes of liver transplant recipients with pretransplant malignancies: Insights from a single institution’s experience.2024
  5. 5Cumulative Risk Assessment for De Novo and Recurrent Nonliver Cancer After Liver Transplantation Based on Pretransplant Cancer Experience2025